| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
ADAM17-IN-1 (Compound 2155-17) (50 μM) significantly reduced the oxygen consumption rate (OCR) and reserve respiratory capacity (SRC) of BMDCs, inhibited mitochondrial oxidative phosphorylation, and impaired DC metabolic activity [1]. ADAM17-IN-1 (50 μM, pretreated with HDM-stimulated BMDCs and co-cultured with CFSE-labeled CD4+ T cells from OTII mice for 4 days) significantly reduced the proliferation rate of OVA323-339 peptide-specific T cells, decreased the secretion of Th2 cytokines (IL-13), and reduced the proportion of CD4+GATA3+Th2 cells [1]. ADAM17-IN-1 (0.316-3.16 μM, treated with mouse oligodendrocyte precursors (OPCs)) promoted OPC differentiation in a dose-dependent manner, did not induce apoptosis, and did not show significant cytotoxicity [1].
|
|---|---|
| ln Vivo |
ADAM17-IN-1 (Compound 2155-17) (50 μM cosmetic, 16 hours, with 0.75×10⁵ CD11c+ BMDCs administered intranasally on day 0 and challenged with HDM on days 9, 11, 13, and 15 (50 μg/mouse model)) significantly reduced the number of eosinophils in BAL and lung tissue [1]. ADAM17-IN-1 (200 μg/mouse, intranasal formulation, simultaneously challenged with HDM on days 8, 10, 12, and 14) significantly reduced the number of total key cells and eosinophils in BAL/lung [1].
|
| Animal Protocol |
Animal/Disease Models: HDM-induced allergic asthma model in WT mice (C57BL/6, 6-10 weeks old) with adoptive transfer of BMDCs[1]
Doses: 50 μM in vitro pre-treatment for 16 h Route of Administration: Adoptive transfer of 0.75×105 CD11c+ BMDCs via i.n. on Day 0, followed by i.n. HDM challenge (50 μg/mouse) on Days 9, 11, 13, 15 Experimental Results: Exhibited decreased number of total BAL cells and eosinophils. Reduced BAL CCL24 levels and serum HDM-specific IgG1/IgE levels. Declined IL4, IL5, and IL13 production in DLn cells. Alleviated peribronchial inflammatory cell infiltrates and mucous cell metaplasia in lung. Animal/Disease Models: HDM-induced allergic asthma model in WT mice (C57BL/6, 6-10 weeks old) with adoptive transfer of BMDCs[1] Doses: 200 μg/mouse Route of Administration: i.n., Days 8, 10, 12, 14 concurrent with HDM challenge Experimental Results: Reduced total inflammatory cells and eosinophils in BAL and lung. Decreased serum HDM-specific IgG1/IgE levels and lung IL5/IL13 levels. Reduced peribronchial inflammatory cell infiltrates and mucous cell metaplasia in lung. |
| References |
| Molecular Formula |
C40H55N5O4
|
|---|---|
| Molecular Weight |
669.90
|
| CAS # |
1802395-34-1
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4928 mL | 7.4638 mL | 14.9276 mL | |
| 5 mM | 0.2986 mL | 1.4928 mL | 2.9855 mL | |
| 10 mM | 0.1493 mL | 0.7464 mL | 1.4928 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
